A Phase 3 interventional study of telmisartan/amlodipine in Hypertension, sponsored by Boehringer Ingelheim. Completed at 47 sites in 5 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-01-15.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.
Among the 99 studies testing telmisartan in Hypertension, this one is the 25th largest by enrollment, is one of 6 that started in 2010, is one of 40 in phase 3, and was the 40th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:
Chong Kun Dang Pharmaceutical · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 5 · Phase 3 40 · Phase 4 32
First in 1997; this study’s year is marked. 6 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 502 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 184 across the 99 interventional studies. Of the 91 that completed or were terminated, 14 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 99 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
122 studies in Hypertension by Boehringer Ingelheim: 1 open now, 1 under way, 1 of them phase 3. Of 120 finished, 41 (34%) have results posted.
Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 30th largest by enrollment of the 74 interventional ones that give a count, is one of 8 that started in 2010, is one of 43 in phase 3, and was the 57th registered.
Boehringer Ingelheim’s Hypertension studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 99 studies testing telmisartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 122 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The general aim of this trial to determine the efficacy as measured by the percentage of patients reaching blood pressure goal at the end of the treatment period at 12 weeks. In-clinic blood pressures, home blood pressures and safety will be carefully monitored.
Study Design:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
start low dose and uptitrate to high dose on the basis of blood pressure goal
Drug: telmisartan/amlodipine
Drug pages: Telmisartan · Amlodipine
start low dose and uptitrate to high dose on the basis of BP goal
Percentage of Patients Achieving Blood Pressure (BP) Control After 12 Weeks of Treatment Using In-clinic BP Measurements.
Achieving BP control is defined as SBP\<140 mmHg and DBP\<90 mmHg.
Time frame: 12 weeks
BP Control After 4 and 8 Weeks of Treatment Using In-clinic BP Measurements.
Achieving BP control is defined as SBP\<140 mmHg and DBP\<90 mmHg.
Time frame: 4 and 8 weeks
BP Control (Morning and Evening) After 12 Weeks of Treatment Using Home Blood Pressure Measurement (HBPM).
Achieving BP control with HBPM is defined as SBP\<135 mmHg and DBP\<85 mmHg.
Time frame: Week 12
Change From Baseline Over Time in In-clinic Measured Mean SBP and Mean DBP
Time frame: weeks 4, 8 and 12
Change From Baseline Over Time in In-clinic Measured Mean Pulse Rate
Pulse pressure was not analysed for this study instead pulse rate was analysed at weeks 4, 8 and 12.
Time frame: weeks 4, 8 and 12
Change From Baseline Over Time in In-clinic Measured Mean Pulse Pressure
Time frame: weeks 4, 8 and 12
DBP and SBP Control and Response Rates After 4, 8 and 12 Weeks of Treatment Using In-clinic BP Measurements
DBP control is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP \<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=10mmHg. SBP response is defined as SBP\<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=15mmHg.
Time frame: weeks 4, 8 and 12
Percentage of Patients in Blood Pressure Categories Over Time
BP optimal: SBP \<120 mmHg and DBP \<80 mmHg, BP normal: SBP \<130 mmHg and DBP \<85 mmHg but not optimal, BP high-normal: SBP \<140 mmHg and DBP \<90 mmHg but not normal. Grade 1 hypertension: SBP \<160 mmHg and DBP \<100 mmHg but not high-normal, Grade 2 hypertension: SBP \<180 mmHg and DBP \<110 mmHg but not grade 1, Grade 3 hypertension: SBP \>=180 mmHg or DBP \>=110 mmHg.
Time frame: weeks 4, 8 and 12
DBP and SBP Control and Response Rates Morning and Evening Over Time HBPM Measurements
DBP control: DBP \<85 mmHg, SBP control: SBP \<135 mmHg, DBP response: DBP \<85 mmHg or a reduction from baseline \>=10 mmHg, SBP response: SBP \<135 mmHg or a reduction from baseline \>= 15 mmHg
Time frame: weeks 4, 8 and 12
Frequency of Patients Requiring Up-titration to Telmisartan 80mg Plus Amlodipine 10mg Combination (T80/A10) to Achieve Blood Pressure Control Over Time
Time frame: weeks 4 and 8
| Milestone | T80/A5 |
|---|---|
| Started | 501 |
| Completed | 449 |
| Not completed | 52 |
| Withdrew: Adverse event | 18 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: Protocol violation | 12 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Withdrawal by subject | 11 |
| Withdrew: Other | 6 |
Achieving BP control is defined as SBP\<140 mmHg and DBP\<90 mmHg.
| Percentage of participants | T80/A5 |
|---|---|
| Percentage of Patients Achieving Blood Pressure (BP) Control After 12 Weeks of Treatment Using In-clinic BP Measurements. | 67.6 (63.3 to 71.7) |
Achieving BP control is defined as SBP\<140 mmHg and DBP\<90 mmHg.
| Number of participants | T80/A5 |
|---|---|
| Week 4 | 262 |
| Week 8 | 330 |
Achieving BP control with HBPM is defined as SBP\<135 mmHg and DBP\<85 mmHg.
| Number of participants | T80/A5 |
|---|---|
| Morning | 179 |
| Evening | 172 |
| mmHg | T80/A5 |
|---|---|
| Change at week 4 SBP (N=485) | -13.58 ± 11.95 |
| Change at week 8 SBP (N=487) | -16.37 ± 12.34 |
| Change at week 12 SBP (N=487) | -16.92 ± 12.24 |
| Change at week 4 DBP (N=485) | -8.24 ± 8.77 |
| Change at week 8 DBP (N=487) | -10.33 ± 8.88 |
| Change at week 12 DBP (N=487) | -10.43 ± 8.83 |
Pulse pressure was not analysed for this study instead pulse rate was analysed at weeks 4, 8 and 12.
| bpm | T80/A5 |
|---|---|
| Change at week 4 (N=482) | 1.43 ± 9.22 |
| Change at week 8 (N=463) | 0.32 ± 9.21 |
| Change at week 12 (N=344) | 0.51 ± 9.25 |
No measurements were reported for this outcome.
DBP control is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP \<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=10mmHg. SBP response is defined as SBP\<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=15mmHg.
| Number of participants | T80/A5 |
|---|---|
| Week 4 DBP control | 313 |
| Week 8 DBP control | 368 |
| Week 12 DBP control | 373 |
| Week 4 SBP control | 247 |
| Week 8 SBP control | 305 |
| Week 12 SBP control | 311 |
| Week 4 DBP response | 329 |
| Week 8 DBP response | 393 |
| Week 12 DBP response | 399 |
| Week 4 SBP response | 337 |
| Week 8 SBP response | 388 |
| Week 12 SBP response | 393 |
BP optimal: SBP \<120 mmHg and DBP \<80 mmHg, BP normal: SBP \<130 mmHg and DBP \<85 mmHg but not optimal, BP high-normal: SBP \<140 mmHg and DBP \<90 mmHg but not normal. Grade 1 hypertension: SBP \<160 mmHg and DBP \<100 mmHg but not high-normal, Grade 2 hypertension: SBP \<180 mmHg and DBP \<110 mmHg but not grade 1, Grade 3 hypertension: SBP \>=180 mmHg or DBP \>=110 mmHg.
| Percentage of participants | T80/A5 |
|---|---|
| BP optimal at week 4 (N=482) | 4.1 |
| BP normal at week 4 (N=482) | 19.7 |
| BP high-normal at week 4 (N=482) | 30.5 |
| Grade 1 hypertension at week 4 (N=482) | 39.0 |
| Grade 2 hypertension at week 4 (N=482) | 6.2 |
| Grade 3 hypertension at week 4 (N=482) | 0.4 |
| BP optimal at week 8 (N=487) | 5.5 |
| BP normal at week 8 (N=487) | 22.2 |
| BP high-normal at week 8 (N=487) | 40.0 |
| Grade 1 hypertension at week 8 (N=487) | 27.7 |
| Grade 2 hypertension at week 8 (N=487) | 4.3 |
| Grade 3 hypertension at week 8 (N=487) | 0.2 |
| BP optimal at week 12 (N=487) | 4.5 |
| BP normal at week 12 (N=487) | 28.5 |
| BP high-normal at week 12 (N=487) | 35.5 |
| Grade 1 hypertension at week 12 (N=487) | 27.1 |
| Grade 2 hypertension at week 12 (N=487) | 4.1 |
| Grade 3 hypertension at week 12 (N=487) | 0.2 |
DBP control: DBP \<85 mmHg, SBP control: SBP \<135 mmHg, DBP response: DBP \<85 mmHg or a reduction from baseline \>=10 mmHg, SBP response: SBP \<135 mmHg or a reduction from baseline \>= 15 mmHg
| Number of participants | T80/A5 |
|---|---|
| DBP control morning at week 4 | 256 |
| DBP control morning at week 8 | 242 |
| DBP control morning at week 12 | 252 |
| DBP control evening at week 4 | 272 |
| DBP control evening at week 8 | 247 |
| DBP control evening at week 12 | 263 |
| SBP control morning at week 4 | 204 |
| SBP control morning at week 8 | 198 |
| SBP control morning at week 12 | 206 |
| SBP control evening at week 4 | 204 |
| SBP control evening at week 8 | 183 |
| SBP control evening at week 12 | 190 |
| DBP response morning at week 4 (N=354) | 256 |
| DBP response morning at week 8 (N=354) | 242 |
| DBP response morning at week 12 (N=354) | 252 |
| DBP response evening at week 4 (N=354) | 272 |
| DBP response evening at week 8 (N=354) | 247 |
| DBP response evening at week 12 (N=354) | 263 |
| SBP response morning at week 4 (N=299) | 204 |
| SBP response morning at week 8 (N=299) | 198 |
| SBP response morning at week 12 (N=299) | 206 |
| SBP response evening at week 4 (N=299) | 204 |
| SBP response evening at week 8 (N=299) | 183 |
| SBP response evening at week 12 (N=299) | 190 |
| Number of participants | T80/A5 |
|---|---|
| Week 4 (n=482) | 186 |
| Week 8 (n=284) | 46 |
Collected over 12 weeks: From drug administration until end of treatment plus one day.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T80/A5 | — | 1/501 (0.2%) | 26/501 (5.2%) |
| T80/A10 | — | 1/232 (0.4%) | 41/232 (17.7%) |
| Event | T80/A5 | T80/A10 |
|---|---|---|
| Femur fractureInjury, poisoning and procedural complications | 0/501 | 1/232 |
| Fibula fractureInjury, poisoning and procedural complications | 0/501 | 1/232 |
| Upper limb fractureInjury, poisoning and procedural complications | 0/501 | 1/232 |
| Duodenal ulcerGastrointestinal disorders | 1/501 | 0/232 |
| Event | T80/A5 | T80/A10 |
|---|---|---|
| Oedema peripheralGeneral disorders | 26/501 | 41/232 |
| Age, Continuous(Years) | T80/A5 |
|---|---|
| Mean | 58.0 ± 11.5 |
| Sex: Female, Male(Participants) | T80/A5 |
|---|---|
| Female | 207 |
| Male | 287 |
| Systolic Blood Pressure (SBP) at time of baseline(mmHg) | T80/A5 |
|---|---|
| Mean | 151.4 ± 10.2 |
| Diastolic Blood Pressure (DBP) at time of baseline(mmHg) | T80/A5 |
|---|---|
| Mean | 91.8 ± 8.8 |
The record gives a start of May 2010 and a primary completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2012, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Telmisartan · Amlodipine